The latest discussion surrounding weight-loss medications is centered on their potential impact on fertility and pregnancy, with the term “Ozempic babies” gaining traction on social media.
READ: OAS to Step in as Mediator in Guatemala’s Power Transition Crisis
Weight-Loss Medications
Medications for type 2 diabetes, such as Ozempic and Mounjaro, are known to induce weight loss as a side effect. Variants of these drugs, namely Wegovy and Zepbound, have been approved for individuals with obesity.
Recent reports suggest that some women taking these medications have unexpectedly become pregnant, despite experiencing fertility issues or while using birth control pills inconsistently.
For instance, Deb Oliviara, a 32-year-old mother from Michigan, started taking Ozempic in November 2023 to shed 20 pounds and is now pregnant, despite previous struggles with fertility and inconsistent birth control usage.
According to NBC News medical contributor Dr. Tara Narula, these medications may improve fertility by addressing obesity or conditions like polycystic ovary syndrome (PCOS), which can disrupt menstrual cycles and ovulation. Additionally, the drugs’ effects on stomach emptying may alter the absorption of oral contraceptives, potentially leading to unintended pregnancies.
It’s recommended that individuals on Ozempic and similar drugs using oral contraceptives switch to non-oral methods or add a barrier method to prevent pregnancy. However, it’s crucial to note that weight-loss medications are not fertility drugs, and women should discontinue their use immediately upon becoming pregnant.
In the case of Wynter Mitchell, who has PCOS and struggled with obesity-related fertility issues, Ozempic proved beneficial in her weight-loss journey, ultimately leading to a successful IVF procedure. Dr. Alex Robles, a reproductive endocrinologist, suggests that while these medications don’t directly boost fertility, they may create a more conducive environment for conception by addressing underlying metabolic issues.
Nevertheless, there are concerns about the lack of data on the effects of these drugs on fertility treatments and pregnancy outcomes. Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, emphasizes that their medications are not approved for weight management and discourages off-label use.
Women planning pregnancy should discontinue Ozempic and Wegovy at least two months before conception to allow the drugs to clear from their system. Additionally, caution should be exercised regarding the potential fetal harm associated with these medications during pregnancy.
Despite their potential benefits, weight-loss drugs like Ozempic should not be viewed as a definitive solution for fertility issues. Lifestyle modifications, including diet and exercise, remain essential, and individuals considering these medications should be well-informed about their potential risks and benefits, particularly regarding pregnancy. Further research is needed to better understand the impact of these drugs on fertility and pregnancy outcomes.
